http://goo.gl/6nO57r
"In order to measure the antidepressant effect, the pharmaceutical companies have unwisely assessed the reduction in the sum score for a large number of symptoms listed on a rating scale. However, the sensitivity of this instrument is markedly marred by the fact that many of these symptoms occur also in subjects without depression, while others are absent also in many depressed patients. For this and other reasons, the usefulness of this rating scale, which was constructed already during the 1950s, has since long been questioned."
"We investigated what happens if one instead analyzes the effect of the treatment on the key item of the scale - depressed mood."
Noteworthy results
According to Elias Eriksson, the results are noteworthy:
- With the conventional measure of efficacy, only 44 percent of the 32 comparisons reveal a significant superiority of the SSRIs over placebo.
- When the Gothenburg researchers instead examined the efficacy on depressed mood, 29 of the 32 comparisons (91 percent) showed a significant difference favoring the active drug.